卓勝微(300782.SZ):擬以3000萬元參設合夥企業、其主投信息技術領域的早中期階段企業
格隆匯2月17日丨卓勝微(300782.SZ)公佈,為促進公司長遠發展,充分藉助專業投資機構的力量及資源優勢,進一步拓寬公司行業領域及提升綜合競爭力,在不影響公司日常經營及發展、有效控制投資風險的前提下,公司全資子公司江蘇芯卓投資有限公司(“江蘇芯卓”)作為有限合夥人以自有資金人民幣3000萬元參與投資設立盈富泰克(北京)科技創新股權投資基金(有限合夥)(暫定名,最終以市場監督管理部門核准的名稱為準,“合夥企業”、“基金”)。
合夥企業將主要投資於信息技術領域的早中期階段企業。合夥企業可以通過股權投資以及其他法律法規及相關規定允許的投資方式進行投資。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.